Vimarsana
Biggest News Aggregation in the World

Page 26 - Cardiovascular Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cardiovascular Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cardiovascular Sciences Today - Breaking & Trending Today

Treating a heart attack before it happens: It may not be a science fiction – Online International News Network - Vimarsana News

Treating a heart attack before it happens: It may not be a science fiction – Online International News Network

ISLAMABAD, MARCH 25 (Online): Although most people survive a heart attackTrusted Source initially, the risk of death significantly increases over the following years.In fact, 65% of peopleTrusted Source who have a heart attack over the age of 65 die

Peel Therapeutics Describes Excessive NETosis Induction in Long COVID - Vimarsana News

Peel Therapeutics Describes Excessive NETosis Induction in Long COVID

/PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in...

VUMC-led trial demonstrates the inefficacy of two investigational drugs for treating severe COVID-19 - Vimarsana News

VUMC-led trial demonstrates the inefficacy of two investigational drugs for treating severe COVID-19

Despite the success of vaccines for preventing COVID-19, and of drugs for treating the disease, outcomes for severely ill patients admitted to the hospital remains poor.

Tripeptide Treats Fatty Liver Disease in Non-Human Primates - Vimarsana News

Tripeptide Treats Fatty Liver Disease in Non-Human Primates

Researchers say studies describe a highly translatable NASH model and highlight the need for clinical evaluation of DT-109.

Drug Candidate for Fatty Liver Disease Shows Promise in Animal Models - Vimarsana News

Drug Candidate for Fatty Liver Disease Shows Promise in Animal Models

A recently developed amino acid compound successfully treats nonalcoholic fatty liver disease in non-human primates, bringing scientists one step closer to the first human treatment for the condition.